Abstracts tagged "infection and tumor necrosis factor (TNF)"

Abstract Number: 1224 • 2015 ACR/ARHP Annual Meeting
Infection Rate in HIV Patients Who Received TNF-a Inhibitor Therapy for Concomitant Autoimmune Diseases
Sintawat Wangsiricharoen¹, Colin Ligon², Ahmad Dehrab³, Lydia Gedmintas⁴, Marisa Tungsiripat⁵, Clifton Bingham⁶, Carlos J. Lozada⁷ and Leonard H. Calabrese⁸, ¹Chiang Mai University, Chiang Mai, Thailand, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, University of Miami Jackson Memorial Hospital, Miami, FL, ⁴Rheumatology, Brigham's Women's Hospital, Boston, MA, ⁵Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Miami Miller School of Medicine, Miami, FL, ⁸Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Few HIV-infected patients have been treated with tumor necrosis factor (TNF)-α inhibitor therapy for autoimmune diseases refractory to conventional therapies. Evidence supporting the safety…
Abstract Number: 1294 • 2015 ACR/ARHP Annual Meeting
Infection and Screening Costs Related to Tumor Necrosis Factor-Alpha Inhibitor Use
Elizabeth G. Salt¹, Amanda T. Wiggins¹, Mary Kay Rayens¹, David Mannino², Huaman Joo Moises³, Allison R. Jones⁴, Scott A. Merkley⁵, Philip Schwieterman⁶ and Leslie J. Crofford⁷, ¹College of Nursing, University of Kentucky, Lexington, KY, ²Colege of Medicine and Public Health, University of Kentucky, Lexington, KY, ³College of Medicine- Infectious Disease, Univesity of Kentucky, Lexington, KY, ⁴University of Kentucky, Lexington, KY, ⁵Lexington Clinic, Lexington, KY, ⁶College of Pharmacy, University of Kentucky, Lexington, KY, ⁷Medicine, Vanderbilt University, Nashville, TN
Background/Purpose: Bacterial and fungal infections (e.g., tuberculosis, histoplasmosis) have been associated with the use of TNF-α inhibitors (TNFI). Although screening for specific infections prior to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].